论文部分内容阅读
目的:了解HCV基因分型与肝损关系,及对α干扰素疗效的影响。方法:41例慢性丙型肝炎用。干扰素治疗,300万U隔天1次肌注,18周为1个疗程。治疗前用线状探针法作HCV基因分型。于治疗前、治疗结束及停药6个月时用PCR法定量和定性检测HCV RNA,并每月复查肝、肾功能和血常规。结果:38/41例(92.7％)可分型,其中1b型33/38例(86.8％);3b型1例;2a/2c、1b/2a型各2例。各基因型间肝功能SB、ALT、AP均值无差异(P>0.05)。治疗结束及停药6个月时HCV RNA阴转率各为70.7％(29/41)和63.3％(19/30),其中1b型分别占82.8％(24/29)和78.9％(15/19);ALT完全复常率各为56.1％(23/41)和56.7％(17/30),1b型分别占78.3%(18/23)和76.5％(13/17)。结论:本市的丙型肝炎病毒基因分型以1b型为主。基因分型与肝损程度无相关性,同时α干扰素治疗病毒基因为1b型的丙型肝炎患者有效。
OBJECTIVE: To understand the relationship between HCV genotyping and liver damage and its effect on the efficacy of IFN-α. Methods: 41 cases of chronic hepatitis C use. Interferon therapy, 300 million U 1 intramuscular injection every other day, 18 weeks for a course of treatment. Before treatment, linear probes were used to genotype HCV. HCV RNA was detected quantitatively and qualitatively by PCR method before treatment, at the end of treatment and 6 months after discontinuation, and liver, kidney function and blood routine were reviewed monthly. Results: 38/41 cases (92.7%) were typed, of which 33 cases were type 1b (86.8%), 1 case was type 3b and 2 cases were type 2a / 2c and 1b / 2a. The genotypes of liver function SB, ALT, AP mean no difference (P> 0.05). At the end of treatment and six months after withdrawal, the HCV RNA negative conversion rates were 70.7% (29/41) and 63.3% (19/30) respectively, with type 1b accounting for 82.8% (24/29) and 78.9% (15 / 19). The complete recanalization rates of ALT were 56.1% (23/41) and 56.7% (17/30), respectively, and type 1b accounted for 78.3% (18/23) and 76.5% (13/17) respectively. Conclusion: The genotypes of hepatitis C virus in this city are mainly type 1b. Genotyping had no correlation with the degree of liver damage, and interferon alpha was also effective in treating HCV genotype 1b hepatitis C patients.